- Home
- JSPR vs CMPS Comparison
JSPR vs CMPS Comparison
Compare JSPR & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JSPR | CMPS |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3M | 1.9B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | JSPR | CMPS |
|---|---|---|
| Price | $0.63 | $14.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | $15.50 | ★ $25.38 |
| AVG Volume (30 Days) | 548.4K | ★ 2.3M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.22 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $4.82 |
| 52 Week High | $2.69 | $15.87 |
Technical Indicators
Market Signals| Indicator | JSPR | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 41.76 | 56.67 |
| Support Level | $0.64 | $12.95 |
| Resistance Level | $1.03 | $14.87 |
| Average True Range (ATR) | 0.05 | 0.71 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 14.10 | 54.37 |
Price Performance
Historical ComparisonAbout JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.